Advanced glycation end products induce endothelial-to-mesenchymal transition via downregulating sirt 1 and upregulating TGF- β in human endothelial cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  He, Wei ^a   Zhang, Jian ^a   Gan, Tian Yi ^a   Xu, Guo Jun ^a   Tang, Bao Peng ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ANTIBODY; BOVINE SERUM ALBUMIN; CALVASCULIN; CD31 ANTIGEN; COLLAGEN TYPE 1; MESSENGER RNA; PROTEIN; RESVERATROL; SELISISTAT; SIRTUIN 1; SMOOTH MUSCLE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; SIRT1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; ENDOTHELIUM CELL; METABOLISM; PHYSIOLOGY;

CELL DIFFERENTIATION; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; SIRTUIN 1; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84924060735     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/684242     Document Type: Article

References (68)

1. K. S. Bryden, D. B. Dunger, R. A. Mayou, R. C. Peveler, and H. A.W. Neil, "Poor prognosis of young adults with type 1 diabetes: a longitudinal study," Diabetes Care, vol. 26,no. 4, pp. 1052-1057, 2003.
2. V.-P. Mäkinen, C. Forsblom, L. M. Thorn et al., "Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study)," Cardiovascular Diabetology, vol. 8, article 54, 2009.
3. K. Kikuchi, S. Tancharoen, T. Ito et al., "Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke," International Journal of Molecular Sciences, vol. 14, no. 9, pp. 18899-18924, 2013.
4. K. Kikuchi, S. Tancharoen, N. Takeshige et al., "The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease," International Journal of Molecular Sciences, vol. 14, no. 7, pp. 13909-13930, 2013.
5. C. Rask-Madsen and G. L. King, "vascular complications of diabetes: mechanisms of injury and protective factors," Cell Metabolism, vol. 17, no. 1, pp. 20-33, 2013.
6. D. Aronson and E. J. Rayfield, "How hyperglycemia promotes atherosclerosis: molecular mechanisms," Cardiovascular Diabetology, vol. 1, article 1, 2002.
7. M. Brownlee,A. Cerami, and H.vlassara, "Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications," The New England Journal of Medicine, vol. 318, no. 20, pp. 1315-1321, 1988.
8. Z. Makita, H. vlassara, E. Rayfield et al., "Hemoglobin-AGE: a circulatingmarker of advanced glycosylation," Science, vol. 258, no. 5082, pp. 651-653, 1992.
9. M. Brownlee, "Advanced protein glycosylation in diabetes and aging," Annual Review of Medicine, vol. 46, pp. 223-234, 1995.
10. Z. Makita, S. Radoff, E. J. Rayfieldet al., "Advancedglycosylation end products in patients with diabetic nephropathy," The New England Journal of Medicine, vol. 325, no. 12, pp. 836-842, 1991.
11. S.-I. Yamagishi, C.-C. Hsu, M. Taniguchi et al., "Receptormediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy," Biochemical and Biophysical Research Communications, vol. 213, no. 2, pp. 681-687, 1995.
12. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury," Circulation, vol. 114, no. 6, pp. 597-605, 2006.
13. A. Stirban, M. Negrean, B. Stratmann et al., "Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes," Diabetes Care, vol. 29, no. 9, pp. 2064-2071, 2006.
14. S. Cellek, "Point of NO return for nitrergic nerves in diabetes: a new insight into diabetic complications," Current Pharmaceutical Design, vol. 10, no. 29, pp. 3683-3695, 2004.
15. U. Denis, M. Lecomte, C. Paget, D. Ruggiero, N. Wiernsperger, and M. Lagarde, "Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction," Free Radical Biology and Medicine, vol. 33, no. 2, pp. 236-247, 2002.
16. R. Ramasamy, S. J. vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A.M. Schmidt, "Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation," Glycobiology, vol. 15, no. 7, pp. 16R- 28R, 2005.
17. C. Min, E. Kang, S.-H. Yu, S.-H. Shinn, and Y.-S. Kim, "Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells," Diabetes Research and Clinical Practice, vol. 46, no. 3, pp. 197-202, 1999.
18. J.-P. Liu, L. Feng, M.-M. Zhu et al., "The in vitro protective effects of curcumin and demethoxycurcumin in Curcuma longa extract on advanced glycation end products-inducedmesangial cell apoptosis and oxidative stress," Planta Medica, vol. 78, no. 16, pp. 1757-1760, 2012.
19. L. L. Zhou,W. Cao, C. Xie et al., "The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis," Kidney International, vol. 82, no. 7, pp. 759-770, 2012.
20. R. P. Casaroli-Marano, R. Pagan, and S. vilaró, "Epithelialmesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells," Investigative Ophthalmology and visual Science, vol. 40, no. 9, pp. 2062-2072, 1999.
21. H. Ha and H. B. Lee, "Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney," Nephrology, vol. 10, no. 2, pp. S7-S10, 2005.
22. Y. Liu, "Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention," Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 1-12, 2004.
23. W. C. Burns, S. M. Twigg, J. M. Forbes et al., "Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease," Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2484-2494, 2006.
24. M. Tezuka, N. Koyama, N. Morisaki et al., "Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells," Biochemical and Biophysical Research Communications, vol. 193, no. 2, pp. 674-680, 1993.
25. S.-I. Yamagishi, Y. Inagaki, T. Okamoto et al., "Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells," The Journal of Biological Chemistry, vol. 277, no. 23, pp. 20309-20315, 2002.
26. S.-I. Yamagishi, H. Yonekura, Y. Yamamoto et al., "Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor,"The Journal of Biological Chemistry, vol. 272, no. 13, pp. 8723-8730, 1997.
27. A. S. Krolewski, J. H. Warram, P. valsania, B. C. Martin, L. M. B. Laffel, and A. R. Christlieb, "Evolving natural history of coronary artery disease in diabetes mellitus," The American Journal of Medicine, vol. 90, no. 2, supplement 1, pp. S56-S61, 1991.
28. C. Curci, G. Castellano, A. Stasi et al., "Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway," Nephrology Dialysis Transplantation, vol. 29, no. 4, pp. 799-808, 2014.
29. B. C. Cooley, J. Nevado, J. Mellad et al., "TGF-β signalingmediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling," Science Translational Medicine, vol. 6, no. 227, Article ID227ra34, 2014.
30. I.-H. Chen, H.-H. Wang, Y.-S. Hsieh, W.-C. Huang, H.-I. Yeh, and Y.-J. Chuang, "PRSS23 is essential for the Snail-dependent endothelial-to-mesenchymal transition during valvulogenesis in zebrafish," Cardiovascular Research, vol. 97, no. 3, pp. 443-453, 2013.
31. J. C. Kovacic, N. Mercader,M. Torres, M. Boehm, and V. Fuster, "Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition from cardiovascular development to disease," Circulation, vol. 125, no. 14, pp. 1795-1808, 2012.
32. J. Ma, T. Liu, and X. Dong, "Advanced glycation end products of bovine serum albumininduced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades," Molecular vision, vol. 16, pp. 2669-2679, 2010.
33. S. Piera-velazquez and S. A. Jimenez, "Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases," Fibrogenesis and Tissue Repair, vol. 5, no. 1, article S7, 2012.
34. M. A. Nieto, "Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives," International Journal of Developmental Biology, vol. 53, no. 8-10, pp. 1541-1547, 2009.
35. J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions," Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
36. M.-J. Goumans, A. J. van Zonneveld, and P. ten Dijke, "Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis?" Trends in Cardiovascular Medicine, vol. 18, no. 8, pp. 293-298, 2008.
37. T. Kokudo, Y. Suzuki, Y. Yoshimatsu, T. Yamazaki, T. Watabe, and K. Miyazono, "Snail is required for TGFβ-induced endothelial- mesenchymal transition of embryonic stem cell-derived endothelial cells," Journal of Cell Science, vol. 121, no. 20, pp. 3317-3324, 2008.
38. D. Medici, E. M. Shore, V. Y. Lounev, F. S. Kaplan, R. Kalluri, and B. R. Olsen, "Conversion of vascular endothelial cells into multipotent stem-like cells," Nature Medicine, vol. 16, pp. 1400-1406, 2010.
39. J. Li, X. Qu, J. Yao et al., "Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy," Diabetes, vol. 59, no. 10, pp. 2612-2624, 2010.
40. Z. Li and S. A. Jimenez, "Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro," Arthritis and Rheumatism, vol. 63, no. 8, pp. 2473-2483, 2011.
41. D. Medici, S. Potenta, and R. Kalluri, "Transforming growth factor- β2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smadindependent signalling," Biochemical Journal, vol. 437, no. 3, pp. 515-520, 2011.
42. J. Li, X. Qu, J. Yao et al., "Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy," Diabetes, vol. 59, no. 10, pp. 2612-2624, 2010.
43. K. Huang, J. Huang, X. Xie et al., "Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF- β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells," Free Radical Biology and Medicine, vol. 65, pp. 528-540, 2013.
44. M. Takeuchi, R. Bucala, T. Suzuki et al., "Neurotoxicity of advanced glycation end-products for cultured cortical neurons," Journal of Neuropathology and Experimental Neurology, vol. 59, no. 12, pp. 1094-1105, 2000.
45. H.-P. Hammes, B. Wellensiek, I. Klöting, E. Sickel, R. G. Bretzel, and M. Brownlee, "The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster," Diabetologia, vol. 41, no. 2, pp. 165-170, 1998.
46. ΔΔCT method," Methods, vol. 25, no. 4, pp. 402-408, 2001.
47. E. Arciniegas, A. B. Sutton, T. D. Allen, and A. M. Schor, "Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro," Journal of Cell Science, vol. 103, part 2, pp. 521-529, 1992.
48. J.-R. A. J. Moonen, G. Krenning, M. G. L. Brinker, J. A. Koerts, M. J. A. van Luyn, and M. C. Harmsen, "Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny," Cardiovascular Research, vol. 86, no. 3, pp. 506-515, 2010.
49. N. Sasaki, M. Takeuchi, H. Chowei et al., "Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques," Neuroscience Letters, vol. 326, no. 2, pp. 117-120, 2002.
50. S.-I. Yamagishi, K. Nakamura, T. Matsui et al., "Pigment epithelium- derived factor inhibits advanced glycation end product- induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression," The Journal of Biological Chemistry, vol. 281, no. 29, pp. 20213-20220, 2006.
51. S. V. De Kreutzenberg, G. Ceolotto, I. Papparella et al., "Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms," Diabetes, vol. 59, no. 4, pp. 1006-1015, 2010.
52. M. Cardellini, R. Menghini, E. Martelli et al., "TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1," Diabetes, vol. 58, no. 10, pp. 2396-2401, 2009.
53. C. Luevano-Contreras and K. Chapman-Novakofski, "Dietary advanced glycation end products and aging," Nutrients, vol. 2, no. 12, pp. 1247-1265, 2010.
54. T. J. Sims, L. M. Rasmussen, H. Oxlund, and A. J. Bailey, "The role of glycation cross-links in diabetic vascular stiffening," Diabetologia, vol. 39, no. 8, pp. 946-951, 1996.
55. S. D. Yan, A. M. Schmidt, G. M. Anderson et al., "Enhanced cellular oxidant stress by the interaction of advanced glycation end productswith their receptors/binding proteins,"TheJournal of Biological Chemistry, vol. 269, no. 13, pp. 9889-9897, 1994.
56. J. H. Li, W. Wang, X. R. Huang et al., "Advanced glycation end products induce tubular epithelial-myofibroblast transition through theRAGE-ERK1/2MAPkinase signaling pathway,"The American Journal of Pathology, vol. 164, no. 4, pp. 1389-1397, 2004.
57. J. Ma, T. Liu, and X. Dong, "Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades," Molecular vision, vol. 16, pp. 2669-2679, 2010.
58. K. Huang, J. Huang, X. Xie et al., "Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells," Free Radical Biology & Medicine, vol. 65, pp. 528-540, 2013.
59. T. Huhtiniemi, C. Wittekindt, T. Laitinen et al., "Comparative and pharmacophore model for deacetylase SIRT1," Journal of Computer-Aided Molecular Design, vol. 20, no. 9, pp. 589-599, 2006.
60. E.-J. Kim, J.-H. Kho,M.-R. Kang, and S.-J. Um, "Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity," Molecular Cell, vol. 28, no. 2, pp. 277-290, 2007.
61. A. Purushotham, T. T. Schug,Q. Xu, S. Surapureddi,X. Guo, and X. Li, "Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation," Cell Metabolism, vol. 9, no. 4, pp. 327-338, 2009.
62. J. N. Feige, M. Lagouge, C. Canto et al., "Specific SIRT1 activation mimics low energy levels and protects against dietinduced metabolic disorders by enhancing fat oxidation," Cell Metabolism, vol. 8, no. 5, pp. 347-358, 2008.
63. J. E. Dominy Jr., Y. Lee, Z. Gerhart-Hines, and P. Puigserver, "Nutrient-dependent regulation of PGC-1α's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5," Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1804, no. 8, pp. 1676-1683, 2010.
64. L. Bordone, M. C. Motta, F. Picard et al., "Sirt1 regulates insulin secretion by repressingUCP2 in pancreatic β cells," PLoS Biology, vol. 4, no. 2, article e31, 2006.
65. K. A. Moynihan, A. A. Grimm, M. M. Plueger et al., "Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice," Cell Metabolism, vol. 2, no. 2, pp. 105-117, 2005.
66. Z. Gerhart-Hines, J. T. Rodgers, O. Bare et al., "Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α," The EMBO Journal, vol. 26, no. 7, pp. 1913-1923, 2007.
67. P. T. Pfluger, D. Herranz, S. velasco-Miguel, M. Serrano, and M. H. Tschöp, "Sirt1 protects against high-fat diet-induced metabolic damage," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9793-9798, 2008.
68. L. Qiao and J. Shao, "SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer- binding protein α transcriptional complex,"The Journal of Biological Chemistry, vol. 281, no. 52, pp. 39915-39924, 2006.